Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease

600 patients aged ≥18 years will be randomised in a 1:1 ratio to nintedanib or placebo. Patients with diagnosis of IPF will be excluded. The study population will be enriched with two-thirds having a usual interstitial pneumonia-like pattern on HRCT. The primary endpoint is the annual rate of declin...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:BMJ Open Respir Res
Asıl Yazarlar: Flaherty, Kevin R, Brown, Kevin K, Wells, Athol U, Clerisme-Beaty, Emmanuelle, Collard, Harold R, Cottin, Vincent, Devaraj, Anand, Inoue, Yoshikazu, Le Maulf, Florence, Richeldi, Luca, Schmidt, Hendrik, Walsh, Simon, Mezzanotte, William, Schlenker-Herceg, Rozsa
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMJ Publishing Group 2017
Konular:
Interstitial Lung Disease
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5604725/
https://ncbi.nlm.nih.gov/pubmed/29018526
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjresp-2017-000212
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller